Veradermics, Incorporated EV/FCF

Que fait Veradermics, Incorporated ? Veradermics, Incorporated is a clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut. The company focuses on developing novel therapeutics for dermatologic and aesthetic conditions. Veradermics is developing treatments for pattern hair loss affecting adults and children. The company's product pipeline includes VDPHL01, an oral, non-hormonal treatment for pattern hair loss. It is also developing VDMN, a dissolvable microarray patch technology for immunotherapy of common warts, VDAA for the treatment of alopecia areata, and VDMC for the treatment of molluscum contagiosum. Veradermics' products target conditions including androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers, clinicians, and the broader medical and clinical research community involved in dermatology, treating both adult and pediatric populations. Veradermics, Incorporated has an IPO date of February 4, 2026, and its ticker symbol is MANE. The company's website is https://www.veradermics.com. The company is incorporated in the United States and operates under the ISIN US9229671048. The sector and industry classifications for Veradermics are currently unknown. Veradermics, Incorporated est l'une des entreprises les plus populaires sur Eulerpool.